Systems biology in drug discovery

被引:401
作者
Butcher, EC [1 ]
Berg, EL
Kunkel, EJ
机构
[1] Stanford Univ, Sch Med, Dept Pathol 5324, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA
[2] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA
[3] BioSeek Inc, Burlingame, CA 94010 USA
关键词
D O I
10.1038/nbt1017
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The hope of the rapid translation of 'genes to drugs' has foundered on the reality that disease biology is complex, and that drug development must be driven by insights into biological responses. Systems biology aims to describe and to understand the operation of complex biological systems and ultimately to develop predictive models of human disease. Although meaningful molecular level models of human cell and tissue function are a distant goal, systems biology efforts are already influencing drug discovery. Large-scale gene, protein and metabolite measurements ('omics') dramatically accelerate hypothesis generation and testing in disease models. Computer simulations integrating knowledge of organ and system-level responses help prioritize targets and design clinical trials. Automation of complex primary human cell-based assay systems designed to capture emergent properties can now integrate a broad range of disease-relevant human biology into the drug discovery process, informing target and compound validation, lead optimization, and clinical indication selection. These systems biology approaches promise to improve decision making in pharmaceutical development.
引用
收藏
页码:1253 / 1259
页数:7
相关论文
共 39 条
[31]   The roles of cells and mediators in a computer model of chronic asthma [J].
Lewis, AK ;
Paterson, T ;
Leong, CC ;
Defranoux, N ;
Holgate, ST ;
Stokes, CL .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2001, 124 (1-3) :282-286
[32]   Statins as novel immunomodulators: From cell to potential clinical benefit [J].
Mach, F .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (04) :607-610
[33]   Drug target validation and identification of secondary drug target effects using DNA microarrays [J].
Marton, MJ ;
DeRisi, JL ;
Bennett, HA ;
Iyer, VR ;
Meyer, MR ;
Roberts, CJ ;
Stoughton, R ;
Burchard, J ;
Slade, D ;
Dai, HY ;
Bassett, DE ;
Hartwell, LH ;
Brown, PO ;
Friend, SH .
NATURE MEDICINE, 1998, 4 (11) :1293-1301
[34]   Small- and large-scale biosimulation applied to drug discovery and development [J].
Musante, CJ ;
Lewis, AK ;
Hall, K .
DRUG DISCOVERY TODAY, 2002, 7 (20) :S192-S196
[35]   Modeling the heart - from genes to cells to the whole organ [J].
Noble, D .
SCIENCE, 2002, 295 (5560) :1678-1682
[36]   Method for analyzing signaling networks in complex cellular systems [J].
Plavec, I ;
Sirenko, O ;
Privat, S ;
Wang, YK ;
Dajee, M ;
Melrose, J ;
Nakao, B ;
Hytopoulos, E ;
Berg, EL ;
Butcher, EC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (05) :1223-1228
[37]   Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors [J].
Schoeberl, B ;
Eichler-Jonsson, C ;
Gilles, ED ;
Müller, G .
NATURE BIOTECHNOLOGY, 2002, 20 (04) :370-375
[38]   Systems biology, proteomics, and the future of health care: Toward predictive, preventative, and personalized medicine [J].
Weston, AD ;
Hood, L .
JOURNAL OF PROTEOME RESEARCH, 2004, 3 (02) :179-196
[39]  
Wiley HS, 2003, TRENDS CELL BIOL, V13, P43